Pharmacogenetics and nicotine addiction treatment

Pharmacogenomics

Volumn 6, Issue 3, 2005, Pages 211-223

  Munafò, Marcus R ^a   Shields, Alexandra E ^b   Berrettini, Wade H ^c   Patterson, Freda ^c   Lerman, Caryn ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bupropion; Nicotine addiction; Nicotine replacement therapy; Smoking cessation

Indexed keywords

AMFEBUTAMONE; ANKYRIN; BETA ENDORPHIN; DOPAMINE 2 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; MU OPIATE RECEPTOR; NICOTINE DERIVATIVE; VENLAFAXINE;

BEHAVIOR THERAPY; BODY WEIGHT DISORDER; BURNING SENSATION; CLINICAL PRACTICE; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ETHICS; EYE DISEASE; FUTUROLOGY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MEDICAL RESEARCH; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; REVIEW; SEX DIFFERENCE; SMOKING CESSATION; SOCIAL ASPECT; TOBACCO DEPENDENCE; WEIGHT GAIN;

BUPROPION; GENOTYPE; HUMANS; PHARMACOGENETICS; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 18044390656     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.3.211     Document Type: Review

References (108)

1. American Cancer Society: Cancer Facts and Figures 2004. American Cancer Society, Atlanta, USA (2004).
2. Munafò MR, Drury M, Chambers R, Wakley G: Smoking Cessation in Primary Care. Radcliffe Medical Press, Oxford, UK (2002).
3. Hopper JA, Gallagher RE: Tobacco cessation: new challenges, new opportunities. J. Cancer Educ. 18, 128-133 (2003).
4. Hughes JR: Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J. Consult. Clin. Psychol. 61, 751-760 (1993).
5. Silagy C, Lancaster T, Stead L, Mant D, Fowler G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2002).
6. Fiore MC, Smith SS, Jorenby DE, Baker TB: The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 271, 1940-1947 (1994).
7. Schneider NG, Olmstead R Mody FV et al.: Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 90, 1671-1682 (1995).
8. Sutherland G, Stapleton JA, Russell MA et al.: Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340, 324-329 (1992).
9. Hjalmarson A, Franzon M, Westin A, Wiklund O: Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 154, 2567-2572 (1994).
10. Blondal T, Franzon M, Westin A: A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir. J. 10, 1585-1590 (1997).
11. Hurt R, Dale L, Croghan G, Croghan IT, Gomez-Dahl LC, Offord KP: Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clin. Proc. 73, 118-125 (1998).
12. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F: A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 269, 1268-1271 (1993).
13. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K: Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 91, 1293-1306 (1996).
14. Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O: The nicotine inhaler in smoking cessation. Arch. Intern. Med. 157, 1721-1728 (1997).
15. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR: Efficacy of a nicotine lozenge for smoking cessation. Arch. Intern. Med. 162, 1267-1276 (2002).
16. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM: Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbuttin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11, 133-141 (1994).
17. Ascher JA, Cole JO, Colin JN et al.: Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56, 395-401 (1995).
18. Sanchez C, Hyttel J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19, 467-489 (1999).
19. Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295, 321-327 (2000).
20. Tonnesen P, Tonstad S, Hjalmarson A et al.: A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J. Intern. Med. 254, 184-192 (2003).
21. Dalsgareth OJ, Hansen NC, Soes-Petersen U et al.: A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob. Res. 6, 55-61 (2004).
22. Jamerson BD, Nides M, Jorenby DE et al.: Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin. Ther. 23, 744-752 (2001).
23. Ahluwalia JS, Harris KJ, Carley D, Okuyemi KS, Mayo MS: Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 288, 468-474 (2002).
24. Lerman C, Roth D, Kaufmann V et al.: Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 67, 219-223 (2002).
25. Lerman C, Patterson F, Berrettini W: Treating tobacco dependence: state of the science and new directions. J. Clin. Oncol. 23, 311-23 (2005).
26. Johnstone EC, Yudkin PL, Hey K et al.: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14, 83-90 (2004).
27. Yudkin PL, Munafò M, Hey K et al.: Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. Br. Med. J. 328, 989-990 (2004).
28. Balfour DJ: Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr. Drug Target CNS Neurol. Disord. 1, 13-421 (2002).
29. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ: Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psych. 48, 648-654 (1991).
30. Thompson J, Thomas N, Singleton A et al.: D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7, 479-484 (1997).
31. Noble EP, Gottschalk LA, Fallon JH, Ritchie TL, Wu JC: D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am. J. Med. Genet. 74, 162-166 (1997).
32. Pohjalainen T, Rinnie JO, Nagren KI: The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatr. 3, 256-260 (1998).
33. Jönsson EG, Nothen MM, Grunhage F et al.: Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatr. 4, 290-296 (1999).
34. Neville MJ, Johnstone EC, Walton RT: Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23, 540-545 (2004).
35. Lerman C, Wileyto EP, Patterson F et al.: The functional μ opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 4, 184-192 (2004).
36. Davenport KE, Houdi AA, Van Loon GR: Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113, 40-46 (1990).
37. Boyadjieva NI, Sarkar DK: The secretory response of hypothalamic β-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life. Sci. 61, 59-66 (1997).
38. Bond C, LaForge KS, Tian M et al.: Single-nucleotide polymorphism in the human μ opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608-9613 (1998).
39. Crowley JJ, Oslin DW, Patkar AA et al.: A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr. Genet. 13, 169-173 (2003).
40. Lerman C, Shields P, Wileyto E et al.: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12, 627-634 (2002).
41. Kirchheiner J, Klein C, Meineke I et al.: Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13, 619-626 (2003).
42. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF: Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45, 122-132 (2003).
43. Lerman C, Shields PG, Wileyto EP et al.: Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 22, 541-548 (2003).
44. Comings DE, Muhleman D, Gysin R: Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. Biol. Psychiatr. 40, 368-372 (1996).
45. Spitz M, Shi H, Yang F et al.: Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J. Natl Cancer Inst. 90, 358-363 (1998).
46. Lerman C, Caporaso NE, Audrain J et al.: Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol. 18, 14-20 (1999).
47. Sabol S, Hamer D: An improved assay shows no association between the CYP246 gene and cigarette smoking behavior. Behav. Genet. 29, 257-261 (1999).
48. Epstein LH, Jaroni JL, Paluch RA et al.: Dopamine transporter genotype as a risk factor for obesity in African-American smokers. Obes. Res. 10, 1232-1240 (2002).
49. Noble EP: D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am. J. Med. Genet. 116, 103-125 (2003).
50. Swan GE, Valdes AM, Ring HZ et al.: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 5, 21-29 (2005).
51. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström, Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 86, 1119-1127 (1991).
52. David SP, Niaura R, Papandonatos GD et al.: Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob. Res. 5, 935-942 (2003).
53. Lerman C, Berrettini W, Pinto A et al.: Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl.) 174, 571-577 (2004).
54. Cinciripini P, Wetter D, Tomlinson G et al.: The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood. Nicotine Tob. Res. 6, 229-239 (2004).
55. Sullivan P, Eaves L, Kendler K, Neale M: Genetic case-control association studies in neuropsychiatry. Arch. Gen. Psychiatry 58, 1015-1024 (2001).
56. Cardon LR, Palmer LJ: Population stratification and spurious allelic association. Lancet 361, 598-604 (2003).
57. Pritchard J, Rosenberg N: Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 65, 220-228 (1999).
58. Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95-108 (2005).
59. Wang WY, Barratt BJ, Clayton DG, Todd JA: Genome-wide association studies: theoretical and practical concerns. Nat. Rev. Genet. 6, 109-118 (2005).
60. Wileyto EP, Patterson F, Niaura R et al.: Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob. Res. 6, 357-366 (2004).
61. Wileyto EP, Patterson F, Niaura R et al.: Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial utilizing bupropion. Nicotine Tob. Res. (2005) (In press).
62. Jarvis MJ, Boreham R, Primatesta P, Feyerabend C, Bryant A: Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. J. Natl. Cancer Inst. 93, 134-138 (2001).
63. Hutchison KE, Niaura R, Swift R: The effects of smoking high nicotine cigarettes on prepulse inhibition, startle latency, and subjective responses. Psychopharmacology (Berl.) 150, 244-252 (2000).
64. Blendy JA, Strasser A, Waters CL et al.: Reduced nicotine reward in obesity: cross-comparison in human and mouse Psychopharmacology (2005) (In press).
65. Tiffany ST, Cox LS, Elash CA: Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J. Consult. Clin. Psychol. 68, 233-240 (2000).
66. Munafò MR, Mogg K, Roberts S, Bradley BP, Murphy M: Selective processing of smoking-related cues in current smokers, ex-smokers and never-smokers on the modified Stroop task. J. Psychopharmacol. 17, 311-317 (2003).
67. Waters AJ, Shiffman S, Bradley BP, Mogg K: Attentional shifts to smoking cues in smokers. Addiction 98, 1409-1417 (2003).
68. Cardon LF, Idury RM, Harris TJ, Witte JS, Elston RC: Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 10, 503-510 (2000).
69. Shields AE, Lerman C, Sullivan PF: Integrating genetics into smoking treatment: emerging ethical, social and legal issues. Nicotine Tob. Res. 6, 675-688 (2004).
70. Lerman C, Shields AE: Genetic testing for cancer susceptibility: the promise and the pitfalls. Nat. Rev. Cancer 4, 235-241 (2004).
71. Beauchamp TL, Walters L: Contemporary Issues in Bioethics (4th edn) Wadsworth, Belmont, USA (1994).
72. World Health Organization: Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services. World Health Organization, Geneva (1998).
73. National Institutes of Health: Enhancing the Oversight of Genetic Tests: Recommendations of the Secretary's Advisory Committee on Genetic Testing. National Institutes of Health, Washington DC (2000).
74. Emery J, Hayflick S: The challenge of integrating genetic medicine into primary care. Br. Med. J. 322, 1027-1030 (2001).
75. Whittaker L: Clinical applications of genetic testing: implications for the family physician. Am. Fam. Physician 53, 2077-2084 (1996).
76. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H: Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer. J. Med. Genet. 38, 787-792 (2001).
77. Hallowell N, Foster C, Eeles R, Ardern-Jones A, Murday V, Watson M: Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J. Med. Ethics 29, 74-79 (2003).
78. Shields AE, Blumenthal D, Weiss KB et al.: Barriers to translating emerging genetic research on smoking into clinical practice: perspectives of primary care physicians. J. Gen. Intern. Med. (2005) (In press).
79. Freedman AN, Wideroff L, Olson L et al.: US physicians' attitudes toward genetic testing for cancer susceptibility. Am. J. Med. Genet. 120A 63-71 (2003).
80. St Peter RF, Reed MC, Kemper P, Blumenthal D: Changes in the scope of care provided by primary care physicians. N. Engl. J. Med. 341, 1980-1985 (1999).
81. Blumenthal D, Causino N, Chang YC et al.: The duration of ambulatory visits to physicians. J. Fam. Prac. 48, 264-271 (1999).
82. Schoonmaker MM, Bernhardt BA, Holtzman NA: Factors influencing health insurers' decisions to cover new genetic technologies. Int. J. Technol. Assess. Health Care 16, 178-189 (2000).
83. Emery J, Walton R, Murphy M et al.: Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. Br. Med. J. 321, 28-32 (2000).
84. Watson EK, Shickle D, Qureshi N, Emery J, Austoker J: The 'new genetics' and primary care: GPs' views on their role and their educational needs. Fam Prac 16, 420-425 (1999).
85. Tambor ES, Rimer BK, Strigo TS: Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am. J. Med. Genet. 68, 43-49 (1997).
86. Berth H, Balck F, Dinkel A: Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population. Genetic Testing 6, 273-280 (2002).
87. Hadley DW, Jenkins J, Dimond E et al.: Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch. Intern. Med. 163, 573-582 (2003).
88. Department of Labor: Genetic Information and the Workplace. Department of Labor, Washington DC, USA (1998).
89. Goldman J: Protecting privacy to improve health care. Health Aff. 17, 47-60 (1998).
90. Elwyn G, Gray J, Clarke A: Shared decision making and non-directiveness in genetic counseling. J. Med. Genet. 37, 135-138 (2000).
91. National Human Genome Research Institute: Genetic Information and the Workplace. National Human Genome Research Institute, Bethesda, USA (1998).
92. National Human Genome Research Institute: Genetic Information and Health Insurance. National Human Genome Research Institute, Bethesda, USA (1998).
93. Hudson KL, Rothenberg KH, Andrews LB, Kahn MJ, Collins FS: Genetic discrimination and health insurance: an urgent need for reform. Science 270, 391-393 (1995).
94. Kite M: Insurance firm admits using genetic screening. The Times (February 8, 2001).
95. Lewin T: Commission sues railroad to end genetic testing in work injury cases. New York Times (February 10, 2001).
96. Comings DE, Muhleman D, Ahn C, Gysin R, Flanagan SD: The dopamine D2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend. 34, 175-180 (1994).
97. Miller WB, Pasta DJ, MacMurray J, Chui C, Wu H, Comings DE: Dopamine receptor genes are associated with age at first sexual intercourse. J. Biosoc. Sci. 31, 43-54 (1999).
98. Noble EP, Ozkaragoz TZ, Ritchie TL et al.: D2 and D4 dopamine receptor polymorphisms and personality. Am. J. Med. Genet. 81, 257-267 (1998).
99. Comings DE, Comings BG, Muhleman D et al.: The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 266, 1793-1800 (1991).
100. Shields PG, Lerman C, Audrain J et al.: Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 7, 453-458 (1998).
101. Perez-Stable EJ, Herrera B, Jacob P 3rd, Benowitz NL: Nicotine metabolism and intake in black and white smokers. JAMA 280, 152-156 (1998).
102. Clark PI, Gautam S, Gerson LW: Effect of menthol cigarettes on biochemical markers of smoke exposure among black and white smokers. Chest 110, 1194-1198 (1996).
103. Novotny TE, Warner KE, Kendrick JS, Remington PL: Smoking by blacks and whites: socioeconomic and demographic differences. Am. J. Pub. Health 78, 1187-1189 (1988).
104. Shields AE, Fortun M, Hammonds E et al.: The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary review. Am. Psychol. 60, 70-73 (2005).
105. Foster MW, Bernsten D, Carter TH: A model agreement for genetic research in socially identifiable populations. Am. J. Hum. Genet. 63, 696-702 (1998).
106. Bowman J, Murray Jr RF: Genetic Variation and Disorders in Peoples of African Origin. Johns Hopkins University Press, Baltimore, USA (1990).
107. Smith DB: Health Care Divided: Race and Healing a Nation. University of Michigan Press, Ann Arbor, USA (1999).
108. Morgan GD, Kobus K, Gerlach KK et al.: Facilitating transdisciplinary research: the experience of the transdisciplinary tobacco use research centers. Nicotine Tob. Res. (Suppl. 1), S11-S19 (2003).